These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7836334)

  • 1. Serum clomipramine and metabolite levels in four nursing mother-infant pairs.
    Wisner KL; Perel JM; Foglia JP
    J Clin Psychiatry; 1995 Jan; 56(1):17-20. PubMed ID: 7836334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma concentrations of clomipramine and desmethylclomipramine in obsessive-compulsive neurosis.
    Luscombe DK; Wright J; Stern RS; Mawson D; Marks IM
    Postgrad Med J; 1980; 56 Suppl 1():140-3. PubMed ID: 7393825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship of plasma clomipramine and N-desmethylclomipramine to response in obsessive-compulsive disorder.
    Mavissakalian M; Jones B; Olson S; Perel JM
    Psychopharmacol Bull; 1990; 26(1):119-22. PubMed ID: 2371366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer.
    Brown JT; Schneiderhan M; Eum S; Bishop JR
    Pharmacogenomics; 2017 May; 18(7):601-605. PubMed ID: 28470111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clomipramine: plasma levels, side effects and outcome in obsessive-compulsive neurosis.
    Stern RS; Marks IM; Wright J; Luscombe DK
    Postgrad Med J; 1980; 56 Suppl 1():134-9. PubMed ID: 7393824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma steady-state concentrations of hydroxylated metabolites of clomipramine.
    Linnoila M; Insel T; Kilts C; Potter WZ; Murphy DL
    Clin Pharmacol Ther; 1982 Aug; 32(2):208-11. PubMed ID: 7094507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.
    Szegedi A; Wetzel H; Leal M; Härtter S; Hiemke C
    J Clin Psychiatry; 1996 Jun; 57(6):257-64. PubMed ID: 8666564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A preliminary report on clinical response and plasma levels of clomipramine and desmethylclomipramine in obsessive-compulsive neurosis.
    Stern RS; Cobb JP; Marks IM; Jones RB; Luscombe DK
    Postgrad Med J; 1977; 53 Suppl 4():97-103. PubMed ID: 341110
    [No Abstract]   [Full Text] [Related]  

  • 9. Clomipramine and exposure for compulsive rituals: II. Plasma levels, side effects and outcome.
    Stern RS; Marks IM; Mawson D; Luscombe DK
    Br J Psychiatry; 1980 Feb; 136():161-6. PubMed ID: 7370482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clomipramine demethylation rate is important on the outcome of obsessive-compulsive disorder treatment.
    Marcourakis T; Bernik MA; Lotufo Neto F; Gedanke Shavitt R; Gorenstein C
    Int Clin Psychopharmacol; 2015 Jan; 30(1):43-8. PubMed ID: 25279584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are gender differences in antiobsessional response related to different clomipramine metabolism?
    Mundo E; Pirola R; Bellodi L; Smeraldi E; Bareggi SR
    J Clin Psychopharmacol; 2002 Jun; 22(3):341-2. PubMed ID: 12006911
    [No Abstract]   [Full Text] [Related]  

  • 12. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels.
    Mavissakalian MR; Jones B; Olson S; Perel JM
    J Clin Psychopharmacol; 1990 Aug; 10(4):261-8. PubMed ID: 2286699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic studies in obsessional patients.
    Luscombe DK; Marks IM
    J Int Med Res; 1977; 5 Suppl 5():91-6. PubMed ID: 598610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clomipramine and desmethylclomipramine: relationship between plasma levels and clinical effect (author's transl)].
    Vandel B; Vandel S; Jounet JM; Allers G; Volmat R
    Encephale; 1981; 7(5):601-8. PubMed ID: 7327152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placental passage of tricyclic antidepressants.
    Loughhead AM; Stowe ZN; Newport DJ; Ritchie JC; DeVane CL; Owens MJ
    Biol Psychiatry; 2006 Feb; 59(3):287-90. PubMed ID: 16271264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clomipramine in obsessive-compulsive ritualisers treated with exposure therapy: relations between dose, plasma levels, outcome and side effects.
    Kasvikis Y; Marks IM
    Psychopharmacology (Berl); 1988; 95(1):113-8. PubMed ID: 3133689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of clomipramine during pregnancy.
    Ter Horst PG; Proost JH; Smit JP; Vries MT; de Jong-van de Berg LT; Wilffert B
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1493-500. PubMed ID: 26416100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxic neonatal effects following maternal clomipramine therapy.
    Schimmell MS; Katz EZ; Shaag Y; Pastuszak A; Koren G
    J Toxicol Clin Toxicol; 1991; 29(4):479-84. PubMed ID: 1749054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactin in childhood obsessive-compulsive disorder: clinical correlates and response to clomipramine.
    Hanna GL; McCracken JT; Cantwell DP
    J Am Acad Child Adolesc Psychiatry; 1991 Mar; 30(2):173-8. PubMed ID: 2016218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pregnancy complicated by obsessive-compulsive disorder.
    Chelmow D; Halfin VP
    J Matern Fetal Med; 1997; 6(1):31-4. PubMed ID: 9029382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.